Business Wire

WELL Building Standard Gaining Momentum in Europe

Share

As Greenbuild Europe came to a close in Berlin, the International WELL Building Institute™ (IWBI™) used the occasion to highlight how the WELL Building Standard™ (WELL™) has elevated health and well-being to the forefront of sustainability conversations across Europe.

WELL continues to advance the healthy building movement as the premier standard for buildings, interior spaces and communities seeking to implement, validate and measure features that promote human health and wellness. The resonance of the program has spurred innovations across the building, design and construction industries, providing projects with customizable approaches to address geographical and cultural health concerns.

To date, WELL has enrolled more than 830 projects encompassing over 155 million square feet of real estate in 32 countries worldwide. In Europe nearly 190 projects across 13 countries are engaged with WELL, representing 25% of global WELL project square footage. The strong growth of WELL over the past year has been led by early adopter markets, notably France, United Kingdom, Spain and the Netherlands – as well as rapid new expansion in Poland, Sweden and Ireland. Finland, Germany, Hungary and Italy registered their first registered projects in 2017, and the Czech Republic and Slovakia markets are being driven by strong local industry leaders.

Nearly 300 industry professionals in Europe have also successfully passed the WELL Accredited Professional (WELL AP) exam, highlighting the growing pool of practitioners and industry professionals looking to develop and demonstrate their understanding of healthy building strategies.

“The growth of WELL across Europe tells a powerful success story of positive international engagement and speaks to the universal need to support and advance human health through the buildings and spaces we inhabit every day,” said IWBI Chairman and CEO Rick Fedrizzi.

He added, “We’re seeing buildings throughout the region utilize WELL as a holistic framework to help improve health and well-being for everyone inside, signaling to the world that these organizations are putting people first.”

Employers can play a critical role by leveraging the workplace environment to recruit and retain the best talent, reduce absenteeism and improve the happiness, satisfaction and productivity of their employees. Similarly, the vast majority of WELL projects in Europe are being driven by landlords and developers as they seek to offer commercial buildings that will attract companies in pursuit of healthy workspace. Individual organizations are also turning to WELL in an effort to cultivate healthy interior workplaces and adapt to a changing work culture.

A recent survey of corporate occupiers in the EMEA region highlighted the wellness agenda as a strong and growing focus, alongside technology and flexible space, in an attempt to enhance the experience of people inside the spaces. Of those surveyed, four out of five occupiers have, or plan to introduce, wellness programs and 92% have some degree of preference for wellness-enabled buildings.1

In addition to multifamily residential and educational facilities, new sectors interested in applying health and well-being best practices include industrial and warehouse facilities, leisure complexes and senior living facilities.

Further, IWBI has established local market partnerships with several green building councils and other key organizations in Europe, including APTA VITAE (Italy), Blue Building Institute (Netherlands), and Polish Green Building Council (PLGBC).

These organizations are working with IWBI within their respective markets to accelerate the uptake of building practice that helps improve the health and wellness of people everywhere. Each organization has committed to promote the adoption of WELL locally, develop and drive educational initiatives, and collaborate with IWBI to prepare members of each local market for the WELL AP program.

About the International WELL Building Institute

The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings and communities in ways that help people thrive. IWBI delivers the cutting-edge WELL Building Standard (WELL), the first to be focused exclusively on the ways that buildings, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. Its work extends to advancing health through design for entire neighborhoods through the WELL Community Standard™ and supporting the growing number of professionals who seek WELL accreditation. Certification of buildings and accrediting of professionals is third-party administered by Green Building Certification Inc. www.wellcertified.com

About WELL Standards

The WELL Building Standard™ (WELL) is a performance-based system for measuring, certifying and monitoring features of buildings around the globe that impact the health and wellness of people. It is grounded in evidence-based research that demonstrates the connection between the buildings where people spend approximately 90 percent of their time and those buildings' health and wellness impacts on those who use them. The WELL Community Standard™ is a district-scale rating system that takes into account the interconnectivity between buildings and their surroundings and the overall impact on human health. The WELL Building Standard and the WELL Community Standard are developed and delivered by the International WELL Building Institute™ and third- party certified by Green Business Certification Inc. (GBCI). www.wellcertified.com.

###

ADDENDUM – WELL Certified Projects in Europe:

France

     

United Kingdom

SCENEO, Bezons

One Carter Lane, London

Carteret – Lyon

Landsec Workplace, London

55 Amsterdam, Paris

Hilson Moran Manchester

VIVACITY, Paris

The Porter Building, Slough

Portes de Paris, Clichy

 

Ireland: One Albert Quay, Cork

Spain: CBRE Madrid

Finland: Green Building Partners Office, Helsinki

 

___________________________
1 EMEA Occupier Survey 2018, Optimising User Experience: The Personalised Workplace, CBRE Research: https://www.cbre.com/research-and-reports/EMEA-Occupier-Survey-2018

Contact information

Press:
IWBI
Kristen Coco, +44 (0) 7377 815 047
kristen.coco@wellcertified.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu